Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892050 | 0.83 | CNR1 (0.47) | KCNH2SCN5ASCN9AKDRTGFBR1 | |
| SCHEMBL2885850 | 0.79 | CDK2 (0.49) | KCNH2SCN5ASCN9AKDRCCR1 | |
| SCHEMBL2886268 | 0.75 | SCN9A (0.49) | KCNH2SCN5ASCN9AKDRCDK2 | |
| SCHEMBL2889322 | 0.75 | KCNH2 (0.49) | KCNH2SCN5ASCN9AKDRCDK2 | |
| SCHEMBL2020224 | 0.75 | TGFBR1 (0.73) | TGFBR1RAB9AGBA1NPC1CYP1A2 | |
| SCHEMBL13231693 | 0.75 | CCR1 (0.73) | TGFBR1CCR1CCR8CYP3A4TP53 | |
| SCHEMBL2891388 | 0.73 | SCN9A (0.50) | KCNH2SCN5ASCN9AKDRCDK2 | |
| SCHEMBL4995151 | 0.73 | KDR (0.64) | KCNH2SCN5ASCN9AKDRBRAF | |
| SCHEMBL4995179 | 0.73 | BRAF (0.52) | KDRBRAFMAPTTP53FGFR2 | |
| SCHEMBL2891356 | 0.72 | KDR (0.61) | KDRCDK2RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | claimed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | claimed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | claimed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNQ5, KCNA5 | KCNH2 8/4885SCN5A 50/4885SCN9A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.